Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.

Sponsor
The Affiliated Hospital Of Guizhou Medical University
Study ID
NCT07633067
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Middle meningeal artery embolization — PROCEDURE
    Middle meningeal artery embolization with coils.
  • Conventional standard pharmacotherapy for migraine — DRUG
    Conventional standard pharmacotherapy for migraine

Study Details

This study is a multicenter, prospective, double-blind, multi-arm, randomized controlled trial that investigates whether middle meningeal artery embolization is superior to current standard pharmacotherapy for migraine. The main objectives of the study are to explore whether middle meningeal artery embolization can reduce migraine patients' dependence on migraine medications and to assess the safety of middle meningeal artery embolization with coils.

Key Dates

First listed
Jun 8, 2026
Start date
Jun 15, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Unilateral Middle Meningeal Artery Embolization + Standard Pharmacotherapy
    Subjects in this arm will receive unilateral middle meningeal artery embolization with coils plus conventional standard pharmacotherapy for migraine.
  • Experimental: Bilateral Middle Meningeal Artery Embolization + Standard Pharmacotherapy
    Subjects in this arm will receive bilateral middle meningeal artery embolization with coils plus conventional standard pharmacotherapy for migraine.
  • Active Comparator: Conventional Standard Pharmacotherapy
    Subjects in this arm will receive only conventional standard pharmacotherapy for migraine, without any middle meningeal artery embolization intervention.

Primary Outcome Measure

Migraine attack frequency (days / month) [ Time Frame: :At baseline,within 90 days, 90-day, 180-day after treatment ]

Central Contacts

Find similar trials

Nationwide
Migraine trialsNeurology trials

Related Studies